Skip to main content
SpringerLink
Log in

"Targeted Therapies" beim NSCLC – Gegenwart und Zukunft

"Targeted Therapies" in NSCLC – present and future

  • Themenschwerpunkt
  • Published:
Wiener Medizinische Wochenschrift Aims and scope Submit manuscript

Summary

During the last decades considerable progress has been made in the treatment of Non Small Cell Lung Cancer (NSCLC) especially resulting from the introduction of chemotherapy. Based on the results of basic-science, a new era of medical oncology has now been entered. Targets of pivotal importance for the development and perpetuation of malignant proliferation have been identified and pharmaceutical compounds against these structures have been developed ("Targeted Therapies"). The resulting broadening of the therapeutic armamentarium has already changed some of the treatment-guidelines. At the same time, a large number of new drugs has entered the stage of clinical development and every oncologist is confronted with a large amount of new data and the resulting difficulties to keep up to date. Accordingly, the aim of this review is to provide an update on the most important recent developments in the field of "Targeted Therapy" against NSCLC.

Zusammenfassung

Nachdem in den letzten Jahrzehnten durch die Entwicklungen auf dem Gebiet der Chemotherapie wesentliche Fortschritte in der medikamentösen Therapie des nichtkleinzelligen Bronchialkarzinoms (Non Small Cell Lung Cancer, NSCLC) gemacht werden konnten, ist aktuell eine neue Ära angebrochen. Basierend auf den Erkenntnissen der Basiswissenschaften wurden Pharmaka entwickelt und in die klinische Erprobung gebracht, die gegen zentrale Schaltstellen im Stoffwechsel der malignen Zelle gerichtet sind (zielgerichtete Therapien, "Targeted Therapies"). Die dadurch entstandene Erweiterung des therapeutischen Armametariums hat in verschiedenen Bereichen bereits zu Änderungen der Therapiestandards geführt. Gleichzeitig befindet sich eine Vielzahl an weiteren Medikamenten in den frühen Phasen der klinischen Testung und die daraus resultierende Flut an Studiendaten stellt für jeden klinisch tätigen Onkologen eine Herausforderung dar. Dementsprechend ist es das Ziel dieser Übersichtsarbeit ein Update über die wichtigsten aktuellen Entwicklungen zum Einsatz von Targeted Therapies beim NSCLC zu geben.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182–1186

    Article  PubMed  CAS  Google Scholar 

  • Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841–844

    Article  PubMed  CAS  Google Scholar 

  • Fontanini G, Bigini D, Vignati S, Basolo F, Mussi A, Lucchi M, Chine S, Angeletti CA, Harris AL, Bevilacqua G (1995) Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 177: 57–63

    Article  PubMed  CAS  Google Scholar 

  • Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxelcarboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542–2550

    Article  PubMed  CAS  Google Scholar 

  • Manegold C, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Reck M, The BO17704 study group (2007) Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 J Clin Oncol ASCO Meeting Abstracts, LBA7514

  • Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184–2191

    Article  PubMed  CAS  Google Scholar 

  • Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM (2007) Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma-xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13: 3942–3950

    Article  PubMed  CAS  Google Scholar 

  • Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Rev Cancer 5: 341–354

    Article  CAS  Google Scholar 

  • Hirsch FR, Varella-Garcia M, Bunn PA Jr, DiMaria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21: 3798–3807

    Article  PubMed  CAS  Google Scholar 

  • Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton D, von Pawel J, Reck M, Sheperd FA, National Cancer Institute of Canada Clinical Trials Group Study BR.21 (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 24: 3831–3837

    Article  PubMed  CAS  Google Scholar 

  • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132

    Article  PubMed  CAS  Google Scholar 

  • Hilbe W, Aigner K, Dittrich C, Eckmayr J, Fiegl M, Flicker M, Forstner B, Greil R, Jamnig H, Krajnik G, Lang A, Mohn-Staudner A, Schinko H, Studnicka M, Pirker R, Ploner F, Rothmund J, Schiller L, Zabernigg A, Zöchbauer-Müller S (2007) Expertenempfehlung 2006 zur rationalen Zweitlinien-Therapie beim nicht-kleinzelligen Bronchuskarzinom. Wien Klin Wochenschr 119: 259–266

    Article  PubMed  Google Scholar 

  • Niho S, Ichinose Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Jiang H, Nischiwaki Y, Fukuoka M (2007) Results of a randomized Phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimens. J Clin Oncol ASCO Meeting Abstracts LBA7509

  • Douillard JY, Kim E, Hirsh V, Mok T, Socinski MG, Gervais R, WuYi-Long W, Longyun L, Sellers M, Lowe E (2007) Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-call lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST). World Conference on Lung Cancer, Presidential Symposium, Abstract 02

  • Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Aversbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237–2246

    Article  PubMed  CAS  Google Scholar 

  • Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527–1537

    Article  PubMed  CAS  Google Scholar 

  • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139

    Article  PubMed  CAS  Google Scholar 

  • Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497–1500

    Article  PubMed  CAS  Google Scholar 

  • Pao W, Miller V, Zakowski M, Doherty J, Polit K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306–13311

    Article  PubMed  CAS  Google Scholar 

  • Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643–655

    Article  PubMed  CAS  Google Scholar 

  • Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HAT, Klein P, Li X, Ramies D, Johnson DH, Miller VA (2005) TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 23: 5892–5899

    Article  PubMed  CAS  Google Scholar 

  • Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM, von Pawel J (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25: 1545–1552

    Article  PubMed  CAS  Google Scholar 

  • Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22: 777–784

    Article  PubMed  CAS  Google Scholar 

  • Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2. J Clin Oncol 22: 785–794

    Article  PubMed  CAS  Google Scholar 

  • Piperdi B, Ling YH, Kroog G, Perez-Soler R (2004) Schedule-dependent interaction between epidermal growth factor inhibitors (EGFRI) and G2/M blocking chemotherapeutic agents (G2/MB) on human NSCLC cell lines in vitro. ASCO Annual Meeting 2004, Abstract 7028

  • Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Janne PA, Bonomi P (2006) Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 24: 5253–5258

    Article  PubMed  CAS  Google Scholar 

  • Rosell R, Daniel C, Ramlua R, Szczesna A, Constenla M, Mennecier B, Pfeifer W, Mueser M, Montaner I, Gatzemeier U (2004) Randomized phase II study of cetuximab in combination with cisplatin and vinorelbine vs. Cisplatin/Vinorelbine alone in the first-line treatment of patients with epidermal growth factor receptor-expressing advanced non-small-cell lung cancer. ASCO Annual Meeting 2004, Abstract 7012

  • Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam YZ, Pautret V, Weber M, Kreisman H, Shepher FA (2007) Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small-cell lung cancer. ASCO Annual Meeting 2007, Abstract 7539

  • Herbst RS, Chansky K, Kelly K, Atkins JN, Davies AM, Dakhil SR, Albain KS, Kim ES, Crowley JJ, Gandara DR (2007) A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer. ASCO Annual Meeting 2007, Abstract 7545

  • Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59: 1935–1940

    PubMed  CAS  Google Scholar 

  • Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6: 701–708

    PubMed  CAS  Google Scholar 

  • Figlin RA, Belldegrun AS, Crawford J, Lohner M, Roskos L, Yang XD, Foon KA, Schwab G, Weiner L (2002) ABXEGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb) in patients with advanced cancer: phase 1 clinical results. ASCO Annual Meeting 2002, Abstract 35

  • Weiner LM, Belldegrun A, Rowinsky E, Crawford J, Lockbaum P, Huang S, Arends R, Schwab G, Figlin R (2005) Updated results from a dose and schedule studiy of Panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies. ASCO Annual Meeting 2005, Abstract 3059

  • Crawford J, Sandler AB, Hammond LA, Schiller J, Belani C, Kozloff M, Hohnson D, Fleishman A, Lee S, Takeshita K (2004) ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting 2004, Abstract 7083

  • Kim T (2004) Technology evaluation: Matuzumab, Merck KgaA. Curr Opin Mol Ther 6: 96–103

    PubMed  CAS  Google Scholar 

  • Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C (2006) A phase I study of the humanized monoclonal anti-epidermal growth factor receptor antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer. Ann Oncol 17: 1007–1013

    Article  PubMed  CAS  Google Scholar 

  • Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2005) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099–7109

    Article  Google Scholar 

  • Gatzemeier U, Blumenschein G, Fosella F, Simantov R, Elting J, Bigwood D, Cihon F, Reck M (2006) Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. ASCO Annual Meeting 2006, Abstract 7002

  • Adjei AA, Molina JR, Hillman SL, Luyun RF, Reuter NF, Rowland KM, Jett JR, Mandrekar SJ, Schild SE (2007) A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study. ASCO Annual Meeting 2007, Abstract 7547

  • Socinski MA, Novella S, Sanchez JM, Brahmer JA, Govindan R, Belani CP, Atkins JN, Gillenwater HH, Palleres C, Chao RC (2006) Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. ASCO Annual Meeting 2006, Abstract 7001

  • Brahmer JR, Govindan R, Novello S, Rosell R, Belani CP, Atkins JN, Gillenwater HH, Tye L, Chao R, Socinski MA (2007) Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study. ASCO Annual Meeting 2007, Abstract 7542

  • Fanucchi M, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH (2006) Randomized phase II studiy of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 24: 5020–5033

    Article  CAS  Google Scholar 

  • Davies AM, McCoy J, Lara PN, Gumerlock PH, Crowley J, Gandara DR, Southwest Oncology Group Thoracic Committee (2006) Bortezomib + gemcitabine/carboplatin results in encouraging survival in advanced non-small cell lung cancer: Results of a phase II Southwest Oncology Group trial (S0339). ASCO Annual Meeting 2006, Abstract 7017

  • Fehrenbacher L, O'Neill V, Belani CP, Bonomi P, Hart L, Melnyk O, Sandler A, Ramies D, Herbst RS (2006) A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrocholride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. ASCO Annual Meeting 2006, Abstract 7062

  • Adjei AA, Molina JR, Mandrekar SJ, Marks R, Reid JR, Croghan G, Hanson LJ, Jett JR, Xia C, Lathia C, Simantov R (2007) Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 13: 2684–2691

    Article  PubMed  CAS  Google Scholar 

  • Lynch TJ, Renton DW, Hirsh V, Bodkin DJ, Middleman E, Chiappori A, Halmos B, Liu H, Eton O, Shepherd WF (2007) Randomized phase II study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting 2007, Abstract 7680

  • Kris MG, Riely GJ, Azzoli CG, Heelan RT, Krug LM, Pao W, Milton DT, Moore E, Rizvi NA, Miller VA (2007) Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial. ASCO Annual Meeting 2007, Abstract 7575

Download references

Author information

Authors and Affiliations

  1. Klinische Abteilung für Allgemeine Innere Medizin, Schwerpunkt Onkologie, Universitätsklinik für Innere Medizin, Medizinische Universität Innsbruck, Innsbruck, Austria

    Georg Pall & Wolfgang Hilbe

Authors
  1. Georg Pall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Hilbe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georg Pall.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pall, G., Hilbe, W. "Targeted Therapies" beim NSCLC – Gegenwart und Zukunft. Wien Med Wochenschr 157, 545–553 (2007). https://doi.org/10.1007/s10354-007-0482-y

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10354-007-0482-y

Keywords

Schlüsselwörter

Search

Navigation